NGL Fine-Chem Limited's FY26 product concentration declined

NGL Fine-Chem reported Rs 466 crore in veterinary active pharmaceutical ingredient revenue in FY26, while its three largest products represented 28% of sales, down from 33% in FY25. The presentation identifies 95% in-house manufacturing, rather than a 95% veterinary-API sales share, and shows lower concentration across every reported customer and product grouping.

What does NGL Fine-Chem's portfolio include?

NGL Fine-Chem lists 45 active pharmaceutical ingredients, or APIs, comprising 43 veterinary APIs and two human APIs, along with one intermediate and 11 finished dosage forms. Veterinary APIs therefore account for 43 of the 45 APIs listed, but the presentation does not disclose veterinary APIs as a percentage of total company sales.

The veterinary API categories named are anthelmintics, ectoparasiticides, antiprotozoals and phosphorus supplements. NGL Fine-Chem says it has market leadership in its top products and is growing its position in the next four products, but it does not identify those products or state their individual sales.

NGL Fine-Chem reports about 451 customers and says it supplies five of the top 10 global animal healthcare companies. The customer count sits alongside FY26 concentration data showing that its 10 largest customers accounted for 26% of sales.

How did NGL Fine-Chem's veterinary API revenue change?

NGL Fine-Chem's veterinary API revenue increased to Rs 466 crore in FY26 from Rs 327 crore in FY25, a rise of Rs 139 crore. The presentation labels the FY22-to-FY26 revenue series as having a 13% compound annual growth rate, or CAGR.

Revenue first declined by Rs 33 crore, from Rs 258 crore in FY22 to Rs 225 crore in FY23, before rising for three consecutive financial years. FY26 revenue was Rs 166 crore above FY24 and was the highest figure in the five-year series provided.

The Rs 466 crore figure applies specifically to the veterinary API segment, not to total company sales. Consequently, the supplied presentation supports an assessment of the segment's revenue trend but not a conclusion that animal APIs made up 95% of NGL Fine-Chem's sales.

How concentrated were NGL Fine-Chem's customers and products in FY26?

NGL Fine-Chem's disclosed customer and product concentration declined in every reported group in FY26 versus FY25. The top three products represented 28% of FY26 sales, down five percentage points from 33%, while the top three customers represented 10%, down two percentage points from 12%.

The top-five customer share declined to 15% in FY26 from 19% in FY25, and the top-10 customer share declined to 26% from 30%. Based on those stated percentages, sales outside the 10 largest customers increased to 74% from 70%.

Product concentration remained above customer concentration at each comparable group. The top five products accounted for 45% of FY26 sales, down from 47%, while the top 10 products accounted for 65%, down from 68%; this means products outside the top 10 represented 35% of sales, compared with 32% a year earlier.

What manufacturing platform does NGL Fine-Chem disclose?

NGL Fine-Chem says 95% of its manufacturing is in-house and cites backward-integrated facilities as part of its process controls and cost competitiveness. This 95% measure relates to manufacturing activity, not to the revenue share of veterinary APIs.

The presentation describes five manufacturing facilities at Tarapur and Navi Mumbai, Maharashtra, although the company overview separately highlights three state-of-the-art facilities. It gives aggregate specifications of 20,000 square metres of manufacturing area, 168 kilolitres of glass-lined reactors, 253 kilolitres of stainless-steel reactors and 36 cubic metres of gas-induction reactors.

NGL Fine-Chem states that its facilities operate across a reaction range of minus 20 degrees Celsius to plus 250 degrees Celsius, and that 75% of production comes from zero-liquid-discharge facilities. It lists World Health Organization Good Manufacturing Practices, or WHO-GMP, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and current Good Manufacturing Practice accreditations.

NGL Fine-Chem also says it has had no market rejection in 15 years and reports market shares ranging from 15% to more than 50% in key products. The presentation does not provide the market-share methodology, identify the relevant products or disclose revenue covered by those shares.

What expansion is NGL Fine-Chem planning?

NGL Fine-Chem says it has completed a brownfield expansion at subsidiary Macrotech, adding capacity for intermediates, and that commercial production has started. The presentation does not disclose the capacity added, the commercial-production date or the expected revenue contribution.

NGL Fine-Chem is also developing a larger greenfield expansion at Tarapur for demand from products in its pipeline. It reports Rs 220.72 crore of capital expenditure incurred on the project, funded through debt and internal accruals, but gives no commissioning date or capacity target.

The H1FY27 balance sheet shows net block of Rs 285.70 crore, compared with Rs 164.09 crore in FY26. Over the same periods, long-term borrowings declined to Rs 50.68 crore from Rs 56.40 crore, while short-term borrowings increased to Rs 71.43 crore from Rs 52.02 crore.

Conclusion

NGL Fine-Chem's FY26 disclosures show a veterinary API segment with Rs 466 crore of revenue and a less concentrated sales profile than in FY25. The top-three product share fell to 28% from 33%, the top-10 product share declined to 65% from 68%, and the top-10 customer share decreased to 26% from 30%.

The next disclosed issue to watch is execution of the Tarapur greenfield project, on which NGL Fine-Chem has incurred Rs 220.72 crore, alongside the commercial contribution from Macrotech's completed intermediate-capacity expansion. The presentation does not state project commissioning dates, output capacity, revenue targets or the expected sales mix from either expansion.